Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
chemotherapy
oncological outcomes
pembrolizumab
prognostic factor
real world
urothelial carcinoma
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
13
05
2021
received:
02
02
2021
accepted:
13
05
2021
pubmed:
25
5
2021
medline:
16
10
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
To assess the clinical benefit of pembrolizumab as second-line therapy for advanced urothelial carcinoma. We retrospectively compared the effects of pembrolizumab with those of conventional chemotherapy on the prognosis of patients with advanced urothelial carcinoma at six hospitals between January 2004 and August 2020. We compared the oncological outcomes between the patients treated with pembrolizumab and those treated with conventional chemotherapy using Kaplan-Meier curve analysis and multivariate Cox regression analysis with the inverse probability of treatment weighting method. The numbers of patients in the pembrolizumab and chemotherapy groups were 121 and 67, respectively. Patients in the pembrolizumab group were significantly older (median 72 vs 66 years, P = 0.001), and had poor Eastern Cooperative Oncology Group performance status (median 1 vs 0, P = 0.001). The unadjusted Kaplan-Meier curve analysis showed no significant differences in the median overall survival from the first-line chemotherapy (24.7 months vs 16.3 months, P = 0.159). Inverse probability of treatment weighting-adjusted multivariate Cox proportional hazards analyses showed a significant difference between the pembrolizumab and chemotherapy groups in overall survival (P = 0.003, hazard ratio 0.63). Despite the non-negligible age difference between the trial and our clinical practice, our study supports the benefit of second-line pembrolizumab over chemotherapy in real-world practice.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Platinum
49DFR088MY
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
899-905Subventions
Organisme : Japan Society for the Promotion of Science KAENHI
ID : 20K18130
Organisme : Japan Society for the Promotion of Science KAENHI
ID : 20K09517
Informations de copyright
© 2021 The Japanese Urological Association.
Références
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015; 65: 87-108.
Seront E, Machiels J-P. Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat. Rev. 2015; 41: 341-53.
Ciccarese C, Iacovelli R, Bria E et al. Second-line therapy for metastatic urothelial carcinoma: defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Semin. Oncol. 2019; 46: 65-72.
Bellmunt J, Fougeray R, Rosenberg JE et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol. 2013; 24: 1466-72.
Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 2017; 376: 1015-26.
Ogihara K, Kikuchi E, Shigeta K et al. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol. Oncol. 2020; 38: 602.e1-602.e10.
Tamura D, Jinnouchi N, Abe M et al. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice. Int. J. Clin. Oncol. 2020; 25: 899-905.
Kobayashi K, Suzuki K, Hiraide M et al. Association of immune-related adverse events with pembrolizumab efficacy in the treatment of advanced urothelial carcinoma. Oncology 2020; 98: 237-42.
Patterson K, Prabhu V, Xu R et al. Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy. Eur. Urol. Oncol. 2019; 2: 565-71.
Yasuoka S, Yuasa T, Nishimura N et al. Initial experience of pembrolizumab therapy in Japanese patients with metastatic urothelial cancer. Anticancer Res. 2019; 39: 3887-92.
Department of Health and Human Services US. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health. 2009.
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 2009; 45: 228-47.
Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-60.
Kawai T, Sato Y, Makino K et al. Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. Eur. J. Cancer 2019; 116: 114-5.
Haratani K, Hayashi H, Chiba Y et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018; 4: 374-8.
Sato K, Akamatsu H, Murakami E et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018; 115: 71-4.
Teraoka S, Fujimoto D, Morimoto T et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J. Thorac. Oncol. 2017; 12: 1798-805.
Teulings H-E, Limpens J, Jansen SN et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 2015; 33: 773-81.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 2018; 378: 158-68.
Kijima T, Yamamoto H, Saito K et al. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. Cancer Immunol. Immunother. 2021; 70: 657-65.
Furubayashi N, Kuroiwa K, Tokuda N et al. Treating Japanese patients with pembrolizumab for platinum-refractory advanced urothelial carcinoma in real-world clinical practice. J. Clin. Med. Res. 2020; 12: 300-6.
Tan Q, Liu S, Liang C, Han X, Shi Y. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: a meta-analysis. Thoracic Cancer 2018; 9: 1220-30.
Heppt MV, Heinzerling L, Kähler KC et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur. J. Cancer 2017; 80: 56-65.
Inoue T, Tamiya M, Tamiya A et al. Analysis of early death in Japanese patients with advanced non-small-cell lung cancer treated with nivolumab. Clin. Lung Cancer 2018; 19: e171-e176.
Labadie BW, Liu P, Bao R et al. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J. Transl. Med. 2019; 17: 386.
Pan M, Alavi M, Herrinton LJ. Association of inflammatory markers with disease progression in patients with metastatic melanoma treated with immune checkpoint inhibitors. Perm J. 2018; 22: 17-149.
Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco. Targets Ther. 2018; 23: 955-65.
Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front. Immunol. 2018; 9: 1474.
Morelli C, Formica V, Patrikidou A et al. Gastric inflammatory prognostic index (GIPI) to predict efficacy of PD-1/PD-L1 immune checkpoint inhibitors in metastatic gastroesophageal junction (GOJ)/gastric cancer (GC) patients. J. Clin. Orthod. 2020; 38(15_suppl): 4530.
Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int. J. Urol. 2019; 26: 31-47.